Source: International Congress 2017 – Gene signatures in bronchial diseases
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Duk (Warszawa, Poland). p.Leu747Pro mutation leads to misdiagnosis in EGFR mutation assessment – first Caucasian NSCLC patients reported. 4952

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of NSCLC patients with positive EGFR mutation Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1550-1551 Year: 2012 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1551 Year: 2012 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Model for predicting EGFR mutation status in lung cancer Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019 Year: 2019 Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Clinical efficacy of 1st line EGFR-TKIs for NSCLC habouring EGFR mutation with high PD-L1 expression; A single-centered retrospective study Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002